CDMO Stock Overview
Operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Avid Bioservices, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.23 |
| 52 Week High | US$13.22 |
| 52 Week Low | US$4.07 |
| Beta | 1.36 |
| 11 Month Change | 43.28% |
| 3 Month Change | 34.08% |
| 1 Year Change | -19.19% |
| 33 Year Change | -59.76% |
| 5 Year Change | 62.38% |
| Change since IPO | -47.81% |
Recent News & Updates
Recent updates
Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement
Jul 29
There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise
Mar 07We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt
Feb 28There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise
Dec 28Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?
Nov 10Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)
Oct 15Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook
Jun 23Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?
Jun 12Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding
May 21Are Investors Undervaluing Avid Bioservices, Inc. (NASDAQ:CDMO) By 49%?
May 12Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?
Mar 13Here's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt Burden
Nov 10Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M
Sep 06Laughing Water Capital - Avid Bioservices: Not A Binary Bet But A Real Business
Jul 27Avid Bioservices GAAP EPS of $1.65 beats by $1.65, revenue of $31M beats by $2.04M
Jun 29Avid Bioservices (NASDAQ:CDMO) Seems To Use Debt Quite Sensibly
May 30Shareholder Returns
| CDMO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.7% | 3.1% | -1.4% |
| 1Y | -19.2% | 16.3% | 16.9% |
Return vs Industry: CDMO underperformed the US Biotechs industry which returned 16% over the past year.
Return vs Market: CDMO underperformed the US Market which returned 17.3% over the past year.
Price Volatility
| CDMO volatility | |
|---|---|
| CDMO Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CDMO's share price has been volatile over the past 3 months.
Volatility Over Time: CDMO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 371 | Nick Green | www.avidbio.com |
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018.
Avid Bioservices, Inc. Fundamentals Summary
| CDMO fundamental statistics | |
|---|---|
| Market cap | US$650.43m |
| Earnings (TTM) | -US$140.75m |
| Revenue (TTM) | US$139.91m |
4.6x
P/S Ratio-4.6x
P/E RatioIs CDMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDMO income statement (TTM) | |
|---|---|
| Revenue | US$139.91m |
| Cost of Revenue | US$132.59m |
| Gross Profit | US$7.32m |
| Other Expenses | US$148.07m |
| Earnings | -US$140.75m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.21 |
| Gross Margin | 5.23% |
| Net Profit Margin | -100.60% |
| Debt/Equity Ratio | 252.3% |
How did CDMO perform over the long term?
See historical performance and comparison